Most Read Articles
22 Jul 2020
A picosecond alexandrite laser (PSAL) appears to be superior to Q-switched alexandrite laser (QSAL) for the treatment of nevus of Ota, as shown by its better clinical results and fewer adverse events, according to a study.
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
3 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 28 Jul 2020
Higher levels of plasma vitamin C, total and individual carotenoid biomarkers, and their composite biomarker score appear to reduce the incidence of type 2 diabetes (T2D), according to the results of a prospective case-cohort study in eight European countries.

Product Highlight - Erleada

26 Jun 2020
For your patients with high risk# nmCRPC
Prescribing Erleada may help them delay metastasis and/or live longer1

Erleada is a potent androgen receptor (AR) inhibitor indicated for the treatment of patients with high risk non-metastasis castration-resistant prostate cancer (nmCRPC)

In the SPARTAN Study1:
  • Erleada +ADT improved median Metastasis Free Survival after (MFS) for more than 2 years (24.3 months) compared with placebo + ADT (40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)1
  • Erleada + ADT when compared to ADT alone showed: 25% risk reduction in death and 51% risk reduction of PFS21
  • Erleada + ADT demonstrated statistically significant improvement in time to symptomatic progression, time to metastasis, PFS, time to PSA progression and PSA decline.1
  • Erleada provides convenience with once daily oral dosing.2
  • Erleada +ADT was well tolerated and maintained HRQoL of nmCRPC patients.1

#PSA doubling period ≤10 months; PFS: Progression Free Survival; ADT: Androgen deprivation therapy; PSA: Prostate specific antigen; HRQoL: Health-related Quality of Life


References:
1. Smith MR, et al. N Engl J Med. 2018;378(15):1408–18.
2. ERLEADA (apalutamide) approved prescribing information MalaysiaE uSmPC v Jan 2019


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jul 2020
A picosecond alexandrite laser (PSAL) appears to be superior to Q-switched alexandrite laser (QSAL) for the treatment of nevus of Ota, as shown by its better clinical results and fewer adverse events, according to a study.
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
3 days ago
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 28 Jul 2020
Higher levels of plasma vitamin C, total and individual carotenoid biomarkers, and their composite biomarker score appear to reduce the incidence of type 2 diabetes (T2D), according to the results of a prospective case-cohort study in eight European countries.